BioAge Labs posts preclinical data on oral NLRP3 inhibitor BGE-102 in diabetic retinopathy model

BioAge Labs, Inc.

BioAge Labs, Inc.

BIOA

0.00
  • BioAge Labs published preclinical results for oral NLRP3 inhibitor BGE-102 in a streptozotocin-induced diabetic retinopathy mouse model.
  • BGE-102 cut retinal vascular permeability versus vehicle by 74% at 20 mg/kg, 98.7% at 50 mg/kg; higher dose restored angiography to healthy levels.
  • Claudin-5 staining showed tight-junction integrity restored to 95% to 97% of healthy control levels despite persistent hyperglycemia.
  • Findings support a planned Phase 1b/2a trial in diabetic macular edema.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on June 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.